R&D success puts Alexion at the top of the M&A list

There's nothing like a successful development record when it comes to attracting attention as a potential M&A target. For Alexion, you can also add new research for Soliris, the world's most expensive therapeutic. Designed to treat a rare genetic disease, Alexion (ALXN) has mounted four new clinical trials for another rare disease--atypical hemolytic uremic syndrome. Alexion also has $157 million in cash and equivalents, and its near-term market potential has driven its share price to a...